BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 24919864)

  • 21. Spotlight on ustekinumab in moderate to severe plaque psoriasis.
    Croxtall JD
    Am J Clin Dermatol; 2012 Apr; 13(2):135-7. PubMed ID: 22201419
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial.
    Koehm M; Rossmanith T; Foldenauer AC; Herrmann E; Brandt-Jürgens J; Burmester GR; Kellner H; Kiltz U; Kofler DM; Rech J; Mojtahed-Poor S; Jonetzko C; Burkhardt H; Behrens F;
    Lancet Rheumatol; 2023 Jan; 5(1):e14-e23. PubMed ID: 38251504
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ustekinumab : targeting the IL-17 pathway to improve outcomes in psoriatic arthritis.
    Weitz JE; Ritchlin CT
    Expert Opin Biol Ther; 2014 Apr; 14(4):515-26. PubMed ID: 24555741
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
    Woolacott N; Bravo Vergel Y; Hawkins N; Kainth A; Khadjesari Z; Misso K; Light K; Asseburg C; Palmer S; Claxton K; Bruce I; Sculpher M; Riemsma R
    Health Technol Assess; 2006 Sep; 10(31):iii-iv, xiii-xvi, 1-239. PubMed ID: 16948890
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development Programs.
    Ghosh S; Gensler LS; Yang Z; Gasink C; Chakravarty SD; Farahi K; Ramachandran P; Ott E; Strober BE
    Drug Saf; 2019 Jun; 42(6):751-768. PubMed ID: 30739254
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Brodalumab Is Associated with High Rates of Complete Clearance and Quality of Life Improvement: A Subgroup Analysis of Patients with Psoriasis and Concomitant Psoriatic Arthritis.
    Kokolakis G; Vadstrup K; Hansen JB; Carrascosa JM
    Dermatology; 2022; 238(4):620-629. PubMed ID: 34823247
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase III Trial.
    Kavanaugh A; Puig L; Gottlieb AB; Ritchlin C; Li S; Wang Y; Mendelsohn AM; Song M; Zhu Y; Rahman P; McInnes IB;
    Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1739-49. PubMed ID: 26097039
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of psoriasis and psoriatic arthritis.
    Papoutsaki M; Costanzo A
    BioDrugs; 2013 Jan; 27 Suppl 1():3-12. PubMed ID: 23990277
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial.
    Mease PJ; Rahman P; Gottlieb AB; Kollmeier AP; Hsia EC; Xu XL; Sheng S; Agarwal P; Zhou B; Zhuang Y; van der Heijde D; McInnes IB;
    Lancet; 2020 Apr; 395(10230):1126-1136. PubMed ID: 32178766
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
    Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
    Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
    Kawalec P; Holko P; Moćko P; Pilc A
    Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel biological target for the treatment of psoriatic arthritis.
    Spadaro A; Montepaone M; Lubrano E
    Immunotherapy; 2014; 6(5):515-8. PubMed ID: 24896622
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab.
    Kurzeja M; Rudnicka L; Olszewska M
    Am J Clin Dermatol; 2011 Apr; 12(2):113-25. PubMed ID: 21348542
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.
    Gladman DD; Mease PJ; Ritchlin CT; Choy EH; Sharp JT; Ory PA; Perdok RJ; Sasso EH
    Arthritis Rheum; 2007 Feb; 56(2):476-88. PubMed ID: 17265483
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ustekinumab: a review in the treatment of plaque psoriasis and psoriatic arthritis.
    Zaghi D; Krueger GG; Callis Duffin K
    J Drugs Dermatol; 2012 Feb; 11(2):160-7. PubMed ID: 22270196
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapy: Ustekinumab after anti-TNF failure: a step closer to the PSUMMIT of psoriatic arthritis therapy?
    Onuora S
    Nat Rev Rheumatol; 2014 Mar; 10(3):125. PubMed ID: 24535545
    [No Abstract]   [Full Text] [Related]  

  • 37. Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study.
    Mease PJ; Chohan S; Fructuoso FJG; Luggen ME; Rahman P; Raychaudhuri SP; Chou RC; Mendelsohn AM; Rozzo SJ; Gottlieb A
    Ann Rheum Dis; 2021 Sep; 80(9):1147-1157. PubMed ID: 33985942
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study.
    Chimenti MS; Ortolan A; Lorenzin M; Triggianese P; Talamonti M; Costa L; Caso F; Favero M; Teoli M; Galluzzo M; Scarpa R; Punzi L; Perricone R; Ramonda R
    Clin Rheumatol; 2018 Feb; 37(2):397-405. PubMed ID: 29302829
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapy.
    Deepak P; Loftus EV
    Drug Des Devel Ther; 2016; 10():3685-3698. PubMed ID: 27956825
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biological agents in psoriatic arthritis.
    Kocijan R; Muschitz C; Rech J
    Wien Med Wochenschr; 2015 Jan; 165(1-2):36-9. PubMed ID: 25205184
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.